Johnson & Johnson

Health Care
Biotechnology: Pharmaceutical Preparations
www.jnj.com

Earnings Score
Moat Score
Safety Score

Market Cap $371.73B
PE 17
Debt $52.25B
Cash $38.47B
EV $385.51B
FCF $20.37B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$21.81B
EBIT	$26.60B
ROE	28%
ROA	14%
FCF	$20.37B
Equity	$78.11B
Growth Stability	57%
PE	17.04
PEG	1.77
PB	4.76
P/FCF	18.25
P/S	4.16
Price/Cash	0.1
Debt/Equity	0.67
Debt/FCF	2.57
Net Margins	50%
Gross Margins	68%
Op. Margins	30%
Earnings CAGR	16%
Sales Growth YoY	2%
Sales Growth QoQ	-3%
Sales CAGR	3%
FCF CAGR	2%
Equity CAGR	1%
Earnings Stability	0.21
Earnings Growth YoY	238%
Earnings Growth QoQ	221%
Earnings CAGR 5Y	10%

Sales CAGR 5Y	1%
FCF CAGR 5Y	-1%
Equity CAGR 5Y	2%
Earnings CAGR 3Y	-5%
Sales CAGR 3Y	-5%
FCF CAGR 3Y	7%
Equity CAGR 3Y	-1%
Market Cap	$371.73B
Revenue	$89.33B
Dividend Yield	3%
Payout Ratio	55%
Assets	$193.67B
Total Debt	$52.25B
Cash	$38.47B
Shares Outstanding	2.41B
EV	385.51B
Earnings Score	11%
Moat Score	97%
Safety Score	76%
Final Score	61%
Working Capital	14.65B
Current Ratio	1.26
Gross Profit	$61.01B
Shares Growth 3y	-4%
Equity Growth QoQ	9%
Equity Growth YoY	12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors.

SEC Filings

Direct access to Johnson & Johnson (JNJ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 30
2024
- 10-K Dec 29
- 10-Q Sep 29
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Oct 01
- 10-Q Jul 02
- 10-Q Apr 02
- 10-K Jan 01

Sector Comparison

How does Johnson & Johnson compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Johnson & Johnson compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 16%

Stability 21%

loading chart...

Johnson & Johnson Discounted Cash Flow

Fully customizable DCF calculator online for Johnson & Johnson.

Years

Calculation mode

= $228B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$20B	$21B	$21B	$21B	$22B	$22B	$22B	$23B	$23B	$24B	$24B	$240B
DCF		$19B	$17B	$16B	$15B	$14B	$13B	$12B	$11B	$10B	$9.3B	$93B
Value	$228B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	01/2022	12/2022	12/2023	12/2024	TTM
Net Margins	22%	23%	2%	19%	18%	18%	22%	19%	41%	16%	50%
ROA	-	15%	12%	12%	11%	10%	13%	12%	9%	9%	14%
ROE	-	23%	2%	26%	25%	23%	28%	23%	51%	20%	28%

Good Net Margins (50.24%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	01/2022	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	1.75	1.95	1.65	1.39	1.84	1.82	2.4	1.69	1.94	2.57
Debt over Equity	0.28	0.39	0.57	0.51	0.47	0.59	0.49	0.54	0.45	0.54	0.67
Growth Stability	-	-	-	100%	100%	100%	100%	100%	100%	57%	57%

Neutral Debt/FCF ratio (2.57)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.67)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (57%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	01/2022	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	3%	6%	7%	1%	1%	14%	1%	-10%	4%	1%
Earnings YoY growth	-	7%	-92%	1K%	-1%	-3%	42%	-14%	96%	-60%	10%
Equity YoY growth	-	-1%	-15%	-1%	-0%	6%	17%	4%	-10%	4%	2%
FCF YoY growth	-	-2%	14%	4%	7%	1%	-2%	-13%	6%	9%	-1%